Zylembio
1 known investors
Zylem develops therapeutics for cancer, ocular, and cardiovascular disease, along with anti-aging treatments aimed at mitochondrial restoration, based on a portfolio of metabolic redox modulators (MRMs). Its MRMs are tunable mimics of natural molecules modeled on high-density lipoproteins that target SR-B1 to modulate oxidative stress and inflammation, with an initial pipeline focus on targeted oncology.
BiotechLongevity
Investors · 1
Frequently asked questions
- What does Zylembio do?
- Zylem develops therapeutics for cancer, ocular, and cardiovascular disease, along with anti-aging treatments aimed at mitochondrial restoration, based on a portfolio of metabolic redox modulators (MRMs). Its MRMs are tunable mimics of natural molecules modeled on high-density lipoproteins that target SR-B1 to modulate oxidative stress and inflammation, with an initial pipeline focus on targeted oncology.
- Who are Zylembio's investors?
- Zylembio's investors include Portal Innovations.